Category - Features

Features

Lineage Cell Therapeutics readies milestone-rich 2021 in 3 clinical programs

Lineage Cell Therapeutics (NYSE American, TASE:LCTX) expects to report important milestones in its cell therapy clinical programs in dry AMD, cervical spinal cord injury and oncology in 2021, as well as improve its...

January 26, 2021

Features

PDS Biotech to report preliminary data from 3 Phase 2 oncology trials in 2021

PDS Biotechnology (NASDAQ: PDSB) expects to report preliminary data in the first or second quarter of 2021 from a collaboration with the NCI, evaluating its lead oncology product, PDS0101, for the treatment of advanced...

January 19, 2021

Features

Tarsus Pharma developing first treatment for Demodex blepharitis, an ocular condition

Tarsus Pharmaceuticals (NASDAQ:TARS) launched the Phase 2b/3 Saturn-1 clinical trial in September 2020 with its lead asset, TP-03, as the potential first therapeutic for Demodex blepharitis, where eyelids become red...

January 12, 2021

Features

Sernova in clinical development for functional cure of Type 1 Insulin-dependent diabetes

Sernova’s (TSXV:SVA; OTCQB:SEOVF) Cell Pouch System, composed of an implantable device, therapeutic cells and immune protection technologies, has the potential to be a “functional cure” for millions of people with Type...

January 5, 2021

Features

Ripple Therapeutics lead candidate attracts strategic investment and licensing partner

Closely-held Ripple Therapeutics inked a transformative strategic investment and licensing deal for its lead product candidate, IBE-814 IVT, an intravitreal implant being developed for the treatment of diabetic macular...

December 15, 2020

Features

Plus Therapeutics targeting potent radiotherapy directly against glioblastoma

Plus Therapeutics (NASDAQ:PSTV) is developing its lead asset, rhenium nanoliposome (RNL), a targeted and potentially more potent radionucleotide therapy, for the treatment of recurrent glioblastoma and several other...

December 8, 2020

Features

Genelux advancing oncolytic vaccinia virus into pivotal ovarian cancer trial in 2021

Closely-held Genelux expects to arrange an end-of-Phase 2 meeting with the FDA in the first quarter of 2021 and then launch a Phase 3 trial in mid-year with its Olvi-Vec vaccinia virus in combination with chemotherapy...

December 1, 2020

Features

Izotropic Breast CT Imaging System targeting earlier cancer detection

Izotropic (CSE:IZO; OTC:IZOZF; FSE:1R3) is developing a dedicated breast imaging system aimed at the better detection – and potentially earlier diagnosis and treatment – of breast cancer.

November 24, 2020

Features

Kintara Therapeutics readies two late-stage cancer drug candidates

Saiid Zarrabian, President and CEO Kintara Therapeutics (NASDAQ:KTRA), fresh off a merger and $25-million private placement, is moving into a global registration trial in newly-diagnosed and recurrent glioblastoma...

November 17, 2020

Features

Hepion Pharmaceuticals employing artificial intelligence to tackle NASH

After close to three decades developing its artificial intelligence platform, Hepion Pharmaceuticals (NASDAQ:HEPA) is deploying its AI-POWR machine learning platform in its clinical program to tackle non-alcoholic...

November 10, 2020

Category - Features

Lineage Cell Therapeutics readies milestone-rich 2021 in 3 clinical programs

PDS Biotech to report preliminary data from 3 Phase 2 oncology trials in 2021

Tarsus Pharma developing first treatment for Demodex blepharitis, an ocular condition

Sernova in clinical development for functional cure of Type 1 Insulin-dependent diabetes

Ripple Therapeutics lead candidate attracts strategic investment and licensing partner

Plus Therapeutics targeting potent radiotherapy directly against glioblastoma

Genelux advancing oncolytic vaccinia virus into pivotal ovarian cancer trial in 2021

Izotropic Breast CT Imaging System targeting earlier cancer detection

Kintara Therapeutics readies two late-stage cancer drug candidates

Hepion Pharmaceuticals employing artificial intelligence to tackle NASH

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter